University of Massachusetts Medical School
Worcester, MA
Accepting patients
DREAMM-10
Phase 3 Clinical Trial Comparing the Safety and Efficacy of Belantamab Mafodotin, Lenalidomide and Dexamethasone Versus Daratumumab, Lenalidomide and Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplant
- Antibody Drug Conjugate (ADC)
- BCMA
- Phase 3
Accepting patients
MagnetisMM-30
A Phase 1B, Open-Label Study of Elranatamab in Combination with Iberdomide in Participants with Relapsed Refractory Multiple Myeloma
- Bispecific Antibody
- Bispecific T Cell Engager (BiTE)
- BCMA
- CD3
- Phase 1
- Has results